Marc H.
- Country
- Germany
- Department
- n/a
Research Overview
- Efficacy and Safety of Early Depemokimab Initiation as Add-on Therapy in Patients with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation
- A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Data & Insights
Has run more than one trial at 13 of 187 partner sites.
Specializations
Chronic Obstructive Pulmonary Disease
Marc Höffgen is involved in clinical research centered on chronic obstructive pulmonary disease, with emphasis on treatment strategies for persistent symptoms and exacerbation control in patients with COPD.
- COPD exacerbation prevention
- Severe and moderate-to-severe COPD
- Cardiopulmonary outcomes
His trial portfolio includes studies of biologic and inhaled approaches aimed at improving disease control in adult patients with obstructive airway disease.
Asthma
His research activity also includes asthma, particularly in patients whose disease remains uncontrolled despite established maintenance therapy.
- Asthma exacerbation reduction
- Uncontrolled asthma on ICS-containing therapy
- Combination inhaled therapy
The clinical focus extends to therapeutic options intended to strengthen symptom management and reduce flare-related burden in adults with ongoing airway inflammation.
Biologic Therapy in Type 2 Inflammation
Marc Höffgen is engaged in trials exploring biologic treatment concepts for type 2 inflammation in obstructive lung disease, including approaches directed at inflammatory pathways linked to exacerbation risk.
- Astegolimab
- Depemokimab
- Verekitug
This area of interest reflects work on targeted options for patients with inflammatory phenotypes of COPD and related airway disease.
Inhaled Combination Therapies
His clinical research also covers inhaled fixed-dose combinations used in chronic airway disease, with attention to maintenance regimens that combine anti-inflammatory and bronchodilator effects.
- ICS/LABA-based therapy
- Triple inhaled therapy
- Fluticasone propionate and albuterol sulfate
These studies align with therapeutic development in asthma and COPD management through optimized inhaled treatment options.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.